Key result
The CHA2DS2-VASc score was an independent predictor of cardiovascular mortality (HR 2.04; 95% CI 1.20-3.45; p=0.008) and all-cause mortality (HR 2.06; 95% CI 1.43-2.97; p=0.001) in CKD patients.
Why the study?
CKD increases cardiovascular and all-cause mortality, and while the CHA2DS2-VASc score predicts outcomes in various non-AF cardiovascular settings, its predictive role in CKD patients required evaluation.
Does the CHA2DS2-VASc score predict cardiovascular and all-cause mortality in stable nondialysis CKD patients?
Cohort (n=87)
Does the CHA2DS2-VASc score predict cardiovascular and all-cause mortality in stable nondialysis CKD patients?
Hazard Ratio: 2.04 (95% CI 1.2–3.45)
p-value: p=0.008
The CHA2DS2-VASc score serves as a significant independent predictor of cardiovascular and all-cause mortality in stable nondialysis CKD patients, extending its utility beyond atrial fibrillation.
INTRODUCTION: Chronic kidney disease (CKD) is a risk factor for cardiovascular and all-cause mortality. Recognition of high-risk patients is important and could lead to a different approach and better treatment. The CHA2DS2-VASc score was originally used to predict cerebral infarction in patients with atrial fibrillation (AF), but it is also a useful predictor of outcome in other cardiovascular conditions, independent of AF. Therefore, the aim of our research was to assess the role of CHA2DS2-VASc score in predicting cardiovascular and all-cause mortality in CKD patients. METHODS: Stable nondialysis CKD patients were included. At the time of inclusion, medical history data and standard blood results were collected and CHA2DS2-VASc score was calculated. Patients were followed till the same end date, until kidney transplantation or until their death. RESULTS: Eighty-seven CKD patients were included (60.3 ± 12.8 years, 66% male). Mean follow-up time was 1,696.5 ± 564.6 days. During the follow-up, 21 patients died and 11 because of cardiovascular reasons. Univariate Cox regression analysis showed that CHA2DS2-VASc score is a significant predictor of cardiovascular and all-cause mortality. In multivariate Cox regression analysis, in which CHA2DS2-VASc score, serum creatinine, urinary albumin/creatinine, hemoglobin, high-sensitivity C-reactive protein, and intact parathyroid hormone were included, CHA2DS2-VASc score was an independent predictor of cardiovascular (HR: 2.04, CI: 1.20-3.45, p = 0.008) and all-cause mortality (HR: 2.06, CI: 1.43-2.97, p = 0.001). The same was true after adding total cholesterol, triglycerides, and smoking status to both the analyses. CONCLUSION: The CHA2DS2-VASc score is a simple, practical, and quick way to identify the risk for cardiovascular and all-cause mortality in CKD patients.
No takes yet. Share an insight, caveat, or question.
Hojs et al. (2021) conducted a cohort in Chronic kidney disease (n=87). CHA2DS2-VASc score was evaluated on cardiovascular mortality (HR 2.04, 95% CI 1.20-3.45, p=0.008). The CHA2DS2-VASc score was an independent predictor of cardiovascular mortality (HR 2.04; 95% CI 1.20-3.45; p=0.008) and all-cause mortality (HR 2.06; 95% CI 1.43-2.97; p=0.001) in CKD patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: